Industry News

CytRx Corporation securities between November 18, 2014, and July 11, 2016, inclusive. CytRx investors have sixty days from the date of this notice to file a lead plaintiff motion. Investors suffering losses on their CytRx investments are encouraged to contact Lesley Portnoy of..."/>
Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of CytRx Corporation Investors and Encourages Investors to Contact the Firm
Apollo Medical Holdings, Inc., an integrated population health management company, today announced the appointment of Mihir Shah, CPA as Chief Financial Officer effective July 21, 2016.. Shah is a seasoned healthcare executive with over 10 years of experience in the healthcare services sector. His expertise includes leadership in finance roles within the managed care, post-acute care and hospice/palliative care sector, as well as..."/>
Apollo Medical Holdings Appoints Mihir Shah As Chief Financial Officer
Eagle Pharmaceuticals Inc. securities between February 23, 2016 and March 18, 2016, inclusive. Eagle investors have until August 1, 2016 to file a lead plaintiff motion."/>
GPM Reminds Investors of the August 1 Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals Inc.
Ossur Hf :Transactions in relation to share buyback program
Allergan plc, a leading global pharmaceutical company, today announced that the Committee for Medicinal Products for Human Use has adopted a Positive Opinion for TRUBERZI ® in the European Union. 4 TRUBERZI ® is an oral medication that relieves the main symptoms of irritable bowel syndrome with diarrhoea in adults. 1 In two pivotal trials, TRUBERZI ® significantly reduced two of the most bothersome symptoms of IBS-D, abdominal pain and..."/>
Allergan Receives Positive Opinion For Truberzi® (Eluxadoline) For Treatment Of Irritable Bowel Syndrome With Diarrhoea (IBS-D) In Adults
Emergent BioSolutions, Inc. concerning possible violations of federal securities laws between January 11, 2016 and June 21, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm before the September 19, 2016 lead plaintiff motion deadline.. To participate in this class action lawsuit, click here."/>
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Emergent BioSolutions, Inc. and Reminds Investors with Losses to Contact the Firm
Coherus BioSciences, Inc., today announced that its second quarter 2016 financial results will be released on August 9, 2016. At 4:30 p.m. Eastern Time, Coherus’ management will host a conference call to discuss the results for the quarter and provide a general business update.. Financial results will be released after market close on Tuesday, August 9, 2016 and posted at http://investors.coherus.com."/>
Coherus BioSciences to Report Second Quarter 2016 Financial Results on August 9th
PTC Therapeutics, Inc. today announced global regulatory updates on Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy and nonsense mutation cystic fibrosis. European update on Translarna for nmDMD. Over the last several months, PTC has been engaged in constructive discussions with the Committee for Medicinal Products for Human Use of the European Medicines Agency regarding the renewal of..."/>
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren)
Centene Corp., which plans to add more than 1..."/>
Is Clayton emerging as the St. Louis region's new 'downtown'? [St. Louis Post-Dispatch]
Press Ganey Holdings, Inc., today announced that it will hold a conference call on Tuesday, August 2, 2016, at 8:30 a.m. Eastern Time to review the Company's second quarter 2016 financial results. A press release announcing the second quarter financial results will be issued after the close of market trading on Monday, August 1, 2016.. To participate in the company's live conference call and webcast, please dial 877-201-0168 using conference code number 28532174, or..."/>
Press Ganey Holdings, Inc. Announces Second Quarter 2016 Earnings Conference Call
Quality Systems, Inc. will release its fiscal 2017 first quarter operating results on Thursday, July 28, 2016 after market close, with a conference call to follow at 5:00 p.m. Eastern Time. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 866-900-9499 or 937-502-2136 for international callers, and referencing participant code 51021073 approximately 15 minutes prior to the call."/>
Quality Systems, Inc. to Host Fiscal 2017 First Quarter Results Conference Call
Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Dr. Neal Walker, President and CEO, will ring the Closing Bell."/>
Aclaris Therapeutics, Inc. (Nasdaq: ACRS) to Ring The Nasdaq Stock Market Closing Bell
ITC Ltd has appointed Sanjiv Puri, a wholetime director of the company, as chief operating officer with immediate effect, the company said in a filing to the Bombay Stock Exchange. On 6 December, Puri took over as executive director from 6 December, replacing P.V. Before that, Puri was the president of ITC's packaged goods business that accounts for about 80% of ITC's business."/>
Sanjiv Puri, new ITC COO, seen as Deveshwar's successor [Mint, New Delhi]
Jaguar Animal Health, Inc., an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, today announced positive topline results of two recently-completed studies to evaluate the safety and effectiveness of Neonorm™ botanical extract in piglets. The studies were sponsored by a Chinese business entity and took place..."/>
Jaguar Animal Health Announces Positive Preliminary Topline Results of Two Chinese-sponsored Farm Studies to Evaluate the Safety and Effectiveness of Neonorm Botanical Extract in Piglets
Cerecor Inc., a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that the Pharmacotherapies for Alcohol and Substance Use Disorders Consortium has provided a grant to Dr. Ronald Marcus to assess the efficacy of CERC-501, a selective kappa opioid receptor antagonist, separately and in combination with one of two anti-hypertensive drugs, in..."/>
Cerecor Announces Research Grant from the Department of Defense to Study CERC-501 in Animal Models for Co-Morbid Post-Traumatic Stress Disorder and Alcohol Use Disorder
Syneron Medical Ltd., a leading global aesthetic device company, announced today that the PicoWay ® picosecond laser received U.S. Food and Drug Administration clearance for a new ultra-short 785 nm wavelength, which is the third FDA cleared wavelength for PicoWay. The new ultra-short 785 nm wavelength is the first of its kind in the aesthetic market, utilizing a titanium sapphire laser for the removal of blue and green inks, and will..."/>
Syneron Candela's PicoWay Picosecond Laser Receives U.S. FDA Clearance for Ultra-Short 785nm Wavelength
Immuron Limited announces the availability of its presentation from RedChip’ s Small Stocks, Big Money Investor Conference. The replay of the Company’ s presentation and Q&A session can be viewed at http://www.redchip.com/events/9/small-stocks-big-money-investor-conference/imc. ax. During the presentation, Immuron’ s CEO, Thomas Liquard, provides an overview of Immuron’ s business and an update on multiple milestones achieved over the..."/>
Immuron Announces Availability of RedChip Conference Presentation
athenahealth, Inc., a leading provider of cloud-based services and mobile applications for medical groups and health systems, today announced its Merit-Based Incentive Payment System Guarantee, which aims to shield healthcare providers and practices from downward payment adjustments under the proposed Medicare reimbursement program of the same name. The guarantee comes months ahead of the Centers for Medicare and Medicaid Services’..."/>
Athenahealth Announces Industry’s First MIPS Guarantee
Fortress Biotech, Inc., launched the first two prescription products in its dermatology franchise, Luxamend™ Wound Cream and Ceracade™ Skin Barrier Emulsion. Both products will be showcased at the 2016 American Academy of Dermatology Summer Meeting to be held at the Hynes Convention Center in Boston, Massachusetts on July 28-31.. Claude Maraoui, President and CEO of Journey Medical Corporation, said,“ The..."/>
Journey Medical Corporation Launches Luxamend™ Wound Cream and Ceracade™ Skin Barrier Emulsion

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials648 Articles
Consumer Discretionary593 Articles
Information Technology569 Articles
Industrials438 Articles
Health Care379 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.